Effects of hormonal contraception on systemic metabolism: Cross-sectional and longitudinal evidence

International Journal of Epidemiology

Volumn 45, Issue 5, 2016, Pages 1445-1457

  Wang, Qin ^a,b   Würtz, Peter ^a   Auro, Kirsi ^c,d,e   Morin Papunen, Laure ^f   Kangas, Antti J ^a   Soininen, Pasi ^a,b   Tiainen, Mika ^a,b   Tynkkynen, Tuulia ^a,b   Joensuu, Anni ^c,d   Havulinna, Aki S ^c,d   Aalto, Kristiina ^g   Salmi, Marko ^g   Blankenberg, Stefan ^h,i   Zeller, Tanja ^h,i   Viikari, Jorma ^j   Kähönen, Mika ^k   Lehtimäki, Terho ^k   Salomaa, Veikko ^c   Jalkanen, Sirpa ^g   Järvelin, Marjo Riitta ^f,l,m   Perola, Markus ^c,d,n   Raitakari, Olli T ^j,o   Lawlor, Debbie A ^p   Kettunen, Johannes ^a,b,c   Ala Korpela, Mika ^a,b,p   more..

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

^h UNIVERSITY HEART CENTER HAMBURG   (Germany)

ⁱ DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^j TURKU UNIVERSITY HOSPITAL   (Finland)

^k TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF OULU   (Finland)

ⁿ UNIVERSITY OF TARTU   (Estonia)

^o UNIVERSITY OF TURKU   (Finland)

^p UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

Amino acids; Combined oral contraceptive pills; Cytokines; Fatty acids; Hormonal contraception; Hormones; Inflammation; Lipoproteins; Metabolomics; Progestin only contraceptives; Risk factors

Indexed keywords

ACETIC ACID DERIVATIVE; ADIPONECTIN; ALBUMIN; AMINO ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CREATININE; DESOGESTREL; ETHINYLESTRADIOL; FATTY ACID; GESTAGEN; GESTODENE; GLYCOPROTEIN; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN DERIVATIVE; LEPTIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VITAMIN D; CYTOKINE;

AMINO ACID; COHORT ANALYSIS; DRUG; FATTY ACID; HORMONE; IMMUNE RESPONSE; METABOLISM; PROTEIN; RISK FACTOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EVIDENCE BASED PRACTICE; FEMALE; HORMONAL CONTRACEPTION; HORMONE METABOLISM; HUMAN; METABOLOMICS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; BLOOD; DRUG EFFECTS; FINLAND; LONGITUDINAL STUDY; METABOLOME; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADULT; CHOLESTEROL, HDL; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-SECTIONAL STUDIES; CYTOKINES; FATTY ACIDS; FEMALE; FINLAND; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; METABOLOME; METABOLOMICS; PROGESTINS; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 85012867357     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw147     Document Type: Article

References (68)

1. Daniels K, Mosher WD. Contraceptive methods women have ever used: United States, 1982-2010. Natl Health Stat Report 2013;14:1-15.
2. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2010;15:S42-53.
3. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
4. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013;27:25-34.
5. Stegeman BH, de Bastos M, Rosendaal FR et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and networkmeta-analysis. BMJ 2013;347:f5298.
6. Lidegaard O, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66.
7. Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013;27:35-45.
8. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users: epidemiology, pathology and mechanisms. Drugs 2000;60:721-869.
9. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab 2013;27:13-24.
10. Morin Papunen L, Martikainen H, McCarthy MI et al. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol 2008;199:529.e1-10.
11. Godsland IF, Crook D, Simpson R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.
12. Haarala A, Eklund C, Pessi T et al. Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C-reactive protein: the Cardiovascular Risk in Young Finns Study. Scand J Clin Lab Invest 2009;69:168-74.
13. Kemmeren JM. Effect of second-and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2003;103:927-33.
14. Beasley A, Estes C, Guerrero J, Westhoff C. The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism. Contraception 2012;85:446-52.
15. Sitruk-Ware R, Plu-Bureau G,Ménard J et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007;92:2074-9.
16. van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006;4:77-82.
17. Guazzelli CAF, Lindsey PC, de Aráujo FF, Barbieri M, Petta CA, Aldrighi JM. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. Contraception 2005;71:118-21.
18. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365-70.
19. Järvelin M-R, Sovio U, King V et al. Early life factors and blood pressure at age 31 years in the 1966 northern Finland birth cohort. Hypertension 2004;44:838-46.
20. Raitakari OT, Juonala M, Rönnemaa T et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol 2008;37:1220-6.
21. Blankenberg S, Zeller T, Saarela O et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388-97.
22. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135-5.
23. Soininen P, Kangas AJ, Würtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009;134:1781-5.
24. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 2015;8:192-206.
25. Würtz P,Mäkinen V-P, Soininen P et al.Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012;61:1372-80.
26. Kettunen J, Tukiainen T, Sarin A-P et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012;44:269-76.
27. Kujala UM, Mäkinen V-P, Heinonen I et al. Long-term leisuretime physical activity and serum metabolome. Circulation 2013;127:340-8.
28. Fischer K, Kettunen J, Würtz P et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of allcause mortality: an observational study of 17,345 persons. PLoS Med 2014;11:e1001606.
29. Würtz P, Wang Q, Kangas AJ et al. Metabolic signatures of adiposity in young adults: mendelian randomization analysis and effects of weight change. PLoS Med 2014;11:e1001765.
30. Würtz P, Havulinna AS, Soininen P et al. Metabolite profiling and cardiovascular event risk: a prospective study of three population-based cohorts. Circulation 2015;131:774-85.
31. Wang Q, Kangas AJ, Soininen P et al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. Int J Epidemiol 2015;44:623-37.
32. Inouye M, Kettunen J, Soininen P et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol 2010;6:441.
33. Black A, Yang Q, Wu Wen S, Lalonde AB, Guilbert E, Fisher W. Contraceptive use among Canadian women of reproductive age: results of a national survey. J Obstet Gynaecol Can 2009;31:627-40.
34. Auro K, Joensuu A, Fischer K et al. A metabolic view on menopause and ageing. Nat Commun 2014;5:4708.
35. Würtz P, Soininen P, Kangas AJ et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013;36:648-55.
36. Mahendran Y, Cederberg H, Vangipurapu J et al. Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care 2013;36:3732-8.
37. Foulon T, Payen N, Laporte F et al. Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception 2001;64:11-16.
38. El-Haggar SM, Mostafa TM. Cardiovascular risk in Egyptian healthy consumers of different types of combined oral contraceptives pills: a comparative study. Endocrine 2015;49:820-7.
39. Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, März W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or microg) on lipoprotein metabolism. Contraception 2004;69:105-13.
40. Gaspard U, Scheen A, Endrikat J et al. A randomized study over cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003;67:423-9.
41. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35.
42. Do R, Willer CJ, Schmidt EM et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013;45:1345-52.
43. Varbo A, Benn M, Tybjaerg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36.
44. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012;380:572-80.
45. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
46. Zanoni P, Khetarpal SA, Larach DB et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 2016;351:1166-71.
47. Chowdhury R, Warnakula S, Kunutsor S et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 2014;160:398-406.
48. Mäkinen V-P, Soininen P, Forsblom C et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 2008;4:167.
49. Ruoppolo M, Campesi I, Scolamiero E et al. Serum metabolomic profiles suggest influence of sex and oral contraceptive use. American Journal of Translational Research 2014;6:614-24.
50. Potera C, Rose DP. Effect of oral alanine loads on plasma amino acids in oral contraceptive users and control women. Am J Clin Nutr 1978;31:794-8.
51. Craft IL, Peters TJ. Quantitative changes in plasma amino acids induced by oral contraceptives. Clin Sci 1971;41:301-7.
52. Moller SE, Moller BM, Olesen M, Fjalland B. Effects of oral contraceptives on plasma neutral amino acids and cholesterol during a menstrual cycle. Eur J Clin Pharmacol 1996; 50:179-84.
53. Moller SE, Maach-Møller B, Olesen M, Madsen B, Madsen P, Fjalland B. Tyrosine metabolism in users of oral contraceptives. Life Sci 1995;56:687-95.
54. Boirie Y, Albright R, Bigelow M, Nair KS. Impairment of phenylalanine conversion to tyrosine in end-stage renal disease causing tyrosine deficiency. Kidney International 2004;66:591-6.
55. Kopple JD. Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr 2007;137:1586S-90S, discussion 1597S-8S.
56. Møller N, Meek S, Bigelow M, Andrews J, Nair KS. The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: a metabolic role of the kidney. Proc Natl Acad Sci USA 2000;97:1242-6.
57. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the reninaldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21.
58. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
59. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet 2013;382:339-52.
60. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
61. Elliott P, Chambers JC, Zhang W et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
62. Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts. BMJ 2014;349:g6330.
63. Ford JA, MacLennan GS, Avenell A et al. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 2014;100:746-55.
64. Navar-Boggan AM, Peterson ED, D'Agostino RB, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 2015;131:451-8.
65. Stegeman BH, Raps M, Helmerhorst FM et al. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women. J Thromb Haemost 2013;11:203-5.
66. Prescott J, Thompson DJ, Kraft P et al. Genome-wide association study of circulating estradiol, testosterone, and sex hormonebinding globulin in postmenopausal women. PLoS ONE 2012;7:e37815.
67. Ruth KS, Campbell PJ, Chew S et al. Genome-wide association study with 1000 genomes imputation identifies signals for nine sex hormone-related phenotypes. Eur J Hum Genet 2016;24:284-90
68. Rich-Edwards JW, Fraser A, Lawlor DA, Catov JM. Pregnancy characteristics and women's future cardiovascular health: an underused opportunity to improve women's health?. Epidemiol Rev 2014;36:57-70.